We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 24, 2021

Tepotinib in Sorafenib-Pretreated Patients With Advanced HCC With MET Overexpression

British Journal of Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

British Journal of Cancer
Phase 1b/2 Trial of Tepotinib in Sorafenib Pretreated Advanced Hepatocellular Carcinoma With MET Overexpression
Br. J. Cancer 2021 Apr 06;[EPub Ahead of Print], T Decaens, C Barone, E Assenat, M Wermke, A Fasolo, P Merle, JF Blanc, V Grando, A Iacobellis, E Villa, J Trojan, J Straub, R Bruns, K Berghoff, J Scheele, E Raymond, S Faivre

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading